Weight loss "game changer" is born

Image credit: Olivier Le Moal / stock.

Obesity is a global health challenge, and there are few drug options.

The results of this large-scale international trial recently published in the New England Journal of Medicine are known as the "game changer" for improving the health of obese people, and may play an important role in helping the UK reduce the impact of diseases such as new coronary pneumonia .

"The findings of this study represent a major breakthrough in improving the health of obese people.

"No drug can achieve this level of weight loss-this is a game-changing drug.

Researchers said that the new coronary pneumonia has highlighted the impact of obesity on health.

Studies have shown that trial participants lost an average of 15.

The lead investigator of the trial, John Wilding of the University of Liverpool, said: "This is a major advancement in the treatment of obesity.

According to the results of this trial, semaglutide has been used as an obesity treatment drug and submitted to the National Institute of Clinical Optimization, the European Medicines Agency and the US Food and Drug Administration for regulatory approval.

The Phase III "STEP" randomized controlled trial involved 1961 overweight or obese adults (average weight 105 kg; body mass index 38 kg/m2), and the trial was conducted in 129 locations in 16 countries in Asia, Europe, North America and South America .

Similar to the way that diabetic patients inject insulin, subjects receive a weekly dose of 2.

Participants also received face-to-face or telephone consultations from registered dietitians every four weeks to help them adhere to a low-calorie diet and increase physical activity, and provide them with guidance, behavioral strategies and motivation.

People who took semaglutide lost an average of 15.

Semaglutide has been clinically approved for patients with type 2 diabetes, but the usual prescribed dose is much lower, only 1 mg.

At present, the "STEP" study has passed Phase I and Phase II clinical trials, with an estimated safe dose of 2.

Related paper information: org/10.